Ovid Therapeutics. has filed a patent for a method and composition using (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid to treat cancer by inhibiting proliferation and metastasis. The claim involves administering the compound in specified doses to a subject in need. GlobalData’s report on Ovid Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ovid Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Ovid Therapeutics's grant share as of January 2024 was 19%. Grant share is based on the ratio of number of grants to total number of patents.
A patent application (Publication Number: US20240009160A1) discloses a method for inhibiting cancer proliferation and metastasis by administering a composition containing a specific compound in a specified dosage range to a subject in need. The composition includes (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or its salt, with dosages ranging from 0.0001 mg/kg to 30 mg/kg. The method targets various types of cancer, including medulloblastoma, breast cancer, lung cancer, and leukemia, among others. The subject of the treatment is primarily human, and the method can be used in conjunction with other cancer therapies like surgery, chemotherapy, and immunotherapy.
Furthermore, the patent application also covers a method for treating cancer by administering the same composition containing the specified compound within a defined dosage range to a subject in need. The dosage ranges from 0.0001 mg/kg to 30 mg/kg, with the method applicable to various cancer types and primarily aimed at human subjects. The treatment can be combined with other cancer therapies like radiotherapy and hormone therapy. The composition can be administered through different routes, including oral, intravenous, and transdermal, providing flexibility in treatment options for cancer patients.
To know more about GlobalData’s detailed insights on Ovid Therapeutics, buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
